SHR-4597 / Jiangsu Hengrui Pharma - LARVOL DELTA

Safety and Pharmacokinetics of SHR-4597, an Inhaled IL-4Rα-Targeted Antibody-Budesonide Conjugate, in Healthy Participants and Asthma Patients : A Randomized, Placebo-Controlled, Double-Blind, Phase I Study (ERS 2026) - "SHR-4597 demonstrated a favorable safety and tolerability profile in both healthy participants and asthma patients, supporting its further clinical development for asthma therapy."

Clinical • First-in-human • P1 data • PK/PD data • Asthma • Immunology • Respiratory Diseases

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-4597 Inhalation in Healthy Subjects and Asthmatic Patients (clinicaltrials.gov) - P1 | N=62 | Completed | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Not yet recruiting ➔ Completed

Trial completion • Asthma • Immunology • Respiratory Diseases

Clinical Study on the Efficacy and Safety of SHR-4597 Inhalant in Adult Patients With Asthma (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd

New P2 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-4597 Inhalation in Healthy Subjects and Asthmatic Patients (clinicaltrials.gov) - P1 | N=80 | Not yet recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd

New P1 trial • Asthma • Immunology • Respiratory Diseases